CD8-mediated inflammatory central nervous system disorders

Current Opinion in Neurology

Volumn 25, Issue 3, 2012, Pages 316-321

  Willing, Anne ^a   Friese, Manuel A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Autoimmunity; CD8; Encephalitis; Immunopathology; Multiple sclerosis; T cell

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM DISEASE; CROSS REACTION; CYTOKINE PRODUCTION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RELAPSE; REVIEW; VIRAL CLEARANCE; WHITE MATTER;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS;

EID: 84860710979     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328352ea8b     Document Type: Review

References (59)

1. Bachem A, Gü ttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c +CD141 +cells as homologues of mouse CD8 + dendritic cells. J Exp Med 2010; 207:1273-1281.
2. Crozat K, Guiton R, Contreras V, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha + dendritic cells. J Exp Med 2010; 207:1283-1292.
3. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-1260.
4. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1 + BDCA3 + leukocytes as putative equivalents of mouse CD8alpha + dendritic cells. J Exp Med 2010; 207:1261-1271.
5. Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8 + T-cell activation after viral infection. Nature 2011; 471:629-632.
6. Rifa'i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8 +CD122 + regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004; 200:1123-1134.
7. Tang X, Maricic I, Purohit N, et al. Regulation of immunity by a novel population of Qa-1-restricted CD8alphaalpha +TCRalphabeta + T cells. J Immunol 2006; 177:7645-7655.
8. Smith TRF, Kumar V. Revival of CD8 + Treg-mediated suppression. Trends Immunol 2008; 29:337-342.
9. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15:277-284.
10. Trandem K, Zhao J, Fleming E, Perlman S. Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis. J Immunol 2011; 186:3642-3652.
11. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
12. McKinney EF, Lyons PA, Carr EJ, et al. A CD8 + T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16:586-591.
13. Lee JC, Lyons PA, Mckinney EF, et al. Gene expression profiling of CD8 + T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121:4170-4179.
14. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002; 51:311-318.
15. Schwab N, Bien CG, Waschbisch A, et al. CD8 + T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 2009; 132:1236-1246.
16. Thilo B, Stingele R, Knudsen K, et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol 2009; 5:458-462.
17. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
18. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851-862.
19. Friese MA, Fugger L. Pathogenic CD8 + T cells in multiple sclerosis. Ann Neurol 2009; 66:132-141.
20. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476:214-219.
21. Link J, Lorentzen AR, Kockum I, et al. Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol 2010; 226:172-176.
22. Healy BC, Liguori M, Tran D, et al. HLA B 44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010; 75:634-640.
23. Friese MA, Jakobsen KB, Friis L, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8 + T cells in multiple sclerosis. Nat Med 2008; 14:1227-1235.
24. McMahon RM, Friis L, Siebold C, et al. Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis. Acta Crystallogr D Biol Crystallogr 2011; 67:447-454.
25. Yeo TW, De Jager PL, Gregory SG, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007; 61:228-236.
26. Friese MA, Fugger L. Autoreactive CD8 + T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128:1747-1763.
27. Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365:2188-2197.
28. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172:146-155.
29. Ifergan I, Kebir H, Alvarez JI, et al. Central nervous system recruitment of effector memory CD8 + T lymphocytes during neuroinflammation is dependent on a4 integrin. Brain 2011; 134:3560-3577.
30. Ji Q, Perchellet A, Goverman JM. Viral infection triggers central nervous system autoimmunity via activation of CD8 + T cells expressing dual TCRs. Nat Immunol 2010; 11:628-634.
31. Wilson EH, Harris TH, Mrass P, et al. Behavior of parasite-specific effector CD8 + T cells in the brain and visualization of a kinesis-associated system of reticular fibers. Immunity 2009; 30:300-311.
32. Meuth SG, Herrmann AM, Simon OJ, et al. Cytotoxic CD8 + T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci 2009; 29:15397-15409.
33. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49:351-357.
34. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
35. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
36. Stü ve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743-747.
37. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4 +CD8 + T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-1387.
38. Kivisäkk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72:1922-1930.
39. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786-1801.
40. Jones JL, Phuah C, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052-2061.
41. Anderson AC, Chandwaskar R, Lee DH, et al. A transgenic model of central nervous system autoimmunity mediated by CD4 + and CD8 + T and B cells. J Immunol 2012; 188:2084-2092.
42. Baughman EJ, Mendoza JP, Ortega SB, et al. Neuroantigen-specific CD8 + regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun 2011; 36:115-124.
43. Hu D, Ikizawa K, Lu L, et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004; 5:516-523.
44. Lu L, Kim H-J, Werneck MBF, Cantor H. Regulation of CD8 + regulatory T cells: Interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc Natl Acad Sci USA 2008; 105:19420-19425.
45. Correale J, Villa A. Isolation and characterization of CD8 + regulatory T cells in multiple sclerosis. J Neuroimmunol 2008; 195:121-134.
46. Chevalier G, Suberbielle E, Monnet C, et al. Neurons are MHC Class I-dependent targets for CD8 T cells upon neurotropic viral infection. PLoS Pathog 2011; 7:e1002393.
47. Pinschewer DD, Schedensack M, Bergthaler A, et al. T cells can mediate viral clearance from ependyma but not from brain parenchyma in a major histocompatibility class I-and perforin-independent manner. Brain 2010; 133:1054-1066.
48. Merkler D, Horvath E, BruckW, et al. 'Viral dé jà vu' elicits organ-specific immune disease independent of reactivity to self. J Clin Invest 2006; 116:1254-1263.
49. Shrestha B, SamuelMA, Michael S, Diamond MS.CD8 + T cells require perforin to clear West Nile virus from infected neurons. J Virol 2006; 80:119-129.
50. Rossi SL, Ross TM, Evans JD. West Nile virus. Clin Lab Med 2010; 30:47-65.
51. Brien JD, Uhrlaub JL, Hirsch A, et al. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009; 206:2735-2745.
52. Klein RS, Lin E, Zhang B, et al. Neuronal CXCL10 directs CD8 + T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005; 79:11457-11466.
53. McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci USA 2008; 105:11270-11275.
54. Du Pasquier RA, KurodaMJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127:1970-1978.
55. Gheuens S, Bord E, Kesari S, et al. Role of CD4 + and CD8 + T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011; 85:7256-7263.
56. Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal PML associated with efalizumab therapy: insights into integrin aLb2 in JC virus control. Neurology 2012; 78:458-467.
57. Metz I, Radue E-W, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.ActaNeuropathol (Berl)2012;123:235- 245.
58. Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDSrelated progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005; 109:449-455.
59. Aly L, Yousef S, Schippling S, et al. Central role of JC virus-specific CD4 + lymphocytes in progressive multifocal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011; 134:2687-2702.